Evaluating the case for trivalent or quadrivalent influenza vaccines

References

• Plotkin SA, Mortimer EA. Vaccines: W B Saunders Company; 1988
   Google Scholar
• Wilschut JM, McElhaney, JE, Palachie JE, AM. Influenza. Second ed: Mosby, Elsevier; 2006
   Google Scholar
• Viral Infections of Humans - Epidemiology and Control. Third ed. New York and London: Plenum Medical; 1991
   Google Scholar
• Bouvier NM, Palese P. The biology of influenza viruses. Vaccine 2008 9/12/; 26, Supplement 4(0): D49-53; PMID:19230160; http://dx.doi.org/10.1016/j.vaccine.2008.07.039
   PubMed Web of Science ®Google Scholar
• Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2003; 36(3):299-305; PMID:12539071
   PubMedGoogle Scholar
• Newland JG, Romero JR, Varman M, Drake C, Holst A, Safranek T, Subbarao K. Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. Clin Infect Dis 2003; 36(7):e87-95; PMID:12652406; http://dx.doi.org/10.1086/368184
   PubMed Web of Science ®Google Scholar
• Oropesa S, Lago P, Goyenechea A, Hernández B, Bello M, Palomera RL Morier Z. Gonzalez L Perez. Rapid death in children by type B influenza virus associated with neurological complications. Int Congress Series 2004; 1263(0):350-4; http://dx.doi.org/10.1016/j.ics.2004.04.005
   Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human Vaccines & Immunotherapeutics. 2012; 8(1):81-8; PMID:22252006
   PubMedGoogle Scholar
• Katagiri S, Ohizumi A, Homma M. An outbreak of type C influenza in a children's home. J Infect Dis 1983; 148(1):51-6; PMID:6309999; http://dx.doi.org/10.1093/infdis/148.1.51
   PubMed Web of Science ®Google Scholar
• GAR. Global Alert and Response - WHO Global Influenza Surveillance Network [cited 2015 05/05/2015]. Available from: http://apps.who.int/csr/disease/influenza/surveillance/en/index.html
   Google Scholar
• FluNet. Influenza: WHO; 2015 [cited 2015 05/05/2015]. Available from: http://www.who.int/influenza/gisrs_laboratory/flunet/en/
   Google Scholar
• GISN. Global Influenza Surveillance Network - Influenza Update 2014 [cited 2014 01/05/2015]. Available from: http://www.who.int/influenza/surveillance_monitoring/updates/2014_12_01_update_GIP_surveillance/en/
   Google Scholar
• WHO. Influenza (Seasonal) 2014 [cited 2015 15/05/2015]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
   Google Scholar
• Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12(9):687-95; PMID:22738893; http://dx.doi.org/10.1016/S1473-3099(12)70121-4
   PubMed Web of Science ®Google Scholar
• Waffarn EE, Baumgarth N. Protective B Cell Responses to Flu—No Fluke! J Immunol 2011; 186(7):3823-9; PMID:21422252; http://dx.doi.org/10.4049/jimmunol.1002090
   PubMed Web of Science ®Google Scholar
• Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990; 175(1):59-68; PMID:2309452; http://dx.doi.org/10.1016/0042-6822(90)90186-U
   PubMed Web of Science ®Google Scholar
• Dijkstra F, Donker GA, Wilbrink B, Van Gageldonk-Lafeber AB, Van Der Sande MA. Long time trends in influenza-like illness and associated determinants in The Netherlands. Epidemiol Infect 2009; 137(4):473-9; PMID:18789176; http://dx.doi.org/10.1017/;S095026880800126X
   PubMed Web of Science ®Google Scholar
• Yang ML, Chen YH, Wang SW, Huang YJ, Leu CH, Yeh NC, Chu CY, Lin CC, Shieh GS, Chen YL, et al. Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. J Virol 2011; 85(19):10010-20; PMID:21795357; http://dx.doi.org/10.1128/;JVI.00301-11
   PubMed Web of Science ®Google Scholar
• Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. The sweet spot: defining virus-sialic acid interactions. Nat Rev Microbiol 2014; 12(11):739-49; PMID:25263223; http://dx.doi.org/10.1038/nrmicro3346
   PubMed Web of Science ®Google Scholar
• Julkunen I, Sareneva T, Pirhonen J, Ronni T, Melén K, Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev 2001; 12(2-3):171-80; PMID:11325600; http://dx.doi.org/10.1016/S1359-6101(00)00026-5
   PubMed Web of Science ®Google Scholar
• Mitchell DM, McMichael AJ, Lamb JR. The immunology of influenza. Br Med Bull 1985; 41(1):80-5; PMID:3882191
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol 2014; 14(5):315-28; PMID:24762827; http://dx.doi.org/10.1038/nri3665
   PubMed Web of Science ®Google Scholar
• Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28(9):2076-9; PMID:20044052; http://dx.doi.org/10.1016/j.vaccine.2009.12.041
   PubMed Web of Science ®Google Scholar
• Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129(4):411-20; PMID:4593871; http://dx.doi.org/10.1093/infdis/129.4.411
   PubMed Web of Science ®Google Scholar
• Glaxo SmithKline. Fluarix tetra - summary of product characteristics Electronic Medicines Compendium2015 [updated 24/03/2015]. Available from: http://www.medicines.org.uk/emc/medicine/27537
   Google Scholar
• Davies JR, Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989; 102(2):325-33; PMID:2703026; http://dx.doi.org/10.1017/S0950268800030004
   PubMed Web of Science ®Google Scholar
• Künzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14(12):1108-10; PMID:8911005; http://dx.doi.org/10.1016/0264-410X(96)00061-8
   PubMed Web of Science ®Google Scholar
• Breteler JK, Tam JS, Jit M, Ket JC, De Boer MR. Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: a systematic review and meta-analysis. Vaccine 2013; 31(45):5168-77; PMID:24012574; http://dx.doi.org/10.1016/j.vaccine.2013.08.056
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(1):36-44; PMID:22032844; http://dx.doi.org/10.1016/S1473-3099(11)70295-X
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366(9492):1165-74; PMID:16198765; http://dx.doi.org/10.1016/S0140-6736(05)67339-4
   PubMed Web of Science ®Google Scholar
• Barker WH, Mullooly JP. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244(22):2547-9; PMID:7431593; http://dx.doi.org/10.1001/jama.1980.03310220045026
   PubMed Web of Science ®Google Scholar
• Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20(13-14):1831-6; PMID:11906772; http://dx.doi.org/10.1016/S0264-410X(02)00041-5
   PubMed Web of Science ®Google Scholar
• Parish HJ. A History of Immunization. Edinburgh and London: E and S Livingstone Ltd; 1965
   Google Scholar
• Sigel MM, Shaffer FW, Kirber MW, Light AB, Henle W. Influenza A in a vaccinated population. JAMA 1948; 136(7):437-41; PMID:22997639; http://dx.doi.org/10.1001/jama.1948.02890240003002
   PubMed Web of Science ®Google Scholar
• Salk JE. An interpretation of the significance of influenza virus variation for the development of an effective vaccine. Bull N Y Acad Med 1952; 28(11):748-65; PMID:12987937
   PubMedGoogle Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207(12):1878-87; PMID:23470848; http://dx.doi.org/10.1093/infdis/jit091
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31(5):770-6; PMID:23228813; http://dx.doi.org/10.1016/j.vaccine.2012.11.074
   PubMed Web of Science ®Google Scholar
• Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine 2014; 32(13):1480-7; PMID:24486352; http://dx.doi.org/10.1016/j.vaccine.2014.01.022
   PubMed Web of Science ®Google Scholar
• Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013; 13:224; PMID:23688546; http://dx.doi.org/10.1186/1471-2334-13-224
   PubMed Web of Science ®Google Scholar
• Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013; 13:343; PMID:23883186; http://dx.doi.org/10.1186/1471-2334-13-343
   PubMed Web of Science ®Google Scholar
• Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29(50):9391-7; PMID:21983154; http://dx.doi.org/10.1016/j.vaccine.2011.09.109
   PubMed Web of Science ®Google Scholar
• Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30(52):7443-6; PMID:23084849; http://dx.doi.org/10.1016/j.vaccine.2012.10.025
   PubMed Web of Science ®Google Scholar
• Lee BY, Bartsch SM, Willig AM. Corrigendum to “The economic value of a quadrivalent versus trivalent influenza vaccine” [Vaccine 2012;30:7443-6]. Vaccine 2013; 31(20):2477-9; http://dx.doi.org/10.1016/j.vaccine.2013.04.013
   Web of Science ®Google Scholar
• Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One 2014; 9(6):e98437; PMID:24905235; http://dx.doi.org/10.1371/journal.pone.0098437
   PubMed Web of Science ®Google Scholar